General Biologic | Consulting

Focus
GB focuses exclusively on the pharmaceutical, healthcare, and biotechnology industries in China. With an understanding of ongoing policy shifts, a global perspective, and a granular knowledge of China’s marketplace, players, and practices, GB maintains a substantial advantage over diversified consulting firms.

Experience
Since our inception in 2002, we have executed projects ranging across multiple areas of the healthcare value chain. Our accumulated case work provides us a unique perspective, allowing us in many cases to accelerate timelines, quickly work through common issues, and dig more deeply into relevant detail for our clients. We focus not only on strategic issues, but also the practicalities of implementing strategies in China’s business environment. Experience has shown us that an excellent strategy for China is useless without significant input from those versed in the realities and constraints on execution in China.

Specific areas
• Opportunity assessments for pharmaceutical products in China's market
• Acquisition and product due diligence
• Partner screening
• Technology and therapeutic area landscape assessment

Information advantages
GB leverages the proprietary data and analysis. Unlike most developed economies, China lacks quality suppliers of business information, particularly in the healthcare industry. Without access to detailed information on companies, policies, products, market data, and people, consulting and advisory work is dangerous at best and destructive at worst. We leverage the data, analysis, and insights created by our information division to ensure project work is based on solid foundations of reliable data.

For further information, contact us